Pachyonychia congenita
There is no radical therapeutic method for pachyonychia congenita, but some care can ease the symptoms. Patients can polish and trim thickened nails, some of them can use retinoids to relieve symptoms but it may increase pain. Neurofibromatosis type I
Selumetinib and trametinib have been shown to reduce and control tumor growth in people with neurofibromatosis type I, reducing the likelihood of malignant lesions. Therapeutic methods
There are some new and developing genetic therapies available in genodermatosis.In the case of X-linked hypohidrotic ectodermal dysplasia, unborn babies diagnosed with this disease can be treated in their mothers womb. Providing regulatory proteins in the womb during a critical period of infant growth may help correct the development of babies sweat glands.Ustekinumab is a biologic therapy that can be used in a variety of genodermatosis such as congenital ichthyosis, psoriasis, deficiency of interleukin-36 receptor antagonist (DITRA) and so on.A new topical method could treat skin abnormalities in rare inherited lipid metabolic diseases. This method obstructs abnormal mevalonate by topical application of lovastatin so that the production and cumulation of poisonous metabolic intermediates can be inhibited as much as possible and takes the place of the lacking lipid in the skin by topical application of cholesterol.
Extensive use of azithromycin has resulted in growing Streptococcus pneumoniae resistance.Aerobic and facultative Gram-positive microorganisms

Staphylococcus aureus (Methicillin-sensitive only)
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pyogenesAerobic and facultative anaerobic Gram-negative microorganisms

Haemophilus ducreyi
Haemophilus influenzae
Moraxella catarrhalis
Neisseria gonorrhoeae
Bordetella pertussis
Legionella pneumophilaAnaerobic microorganisms

Peptostreptococcus species
Prevotella biviaOther microorganisms

Chlamydophila pneumoniae
Chlamydia trachomatis
Mycoplasma genitalium
Mycoplasma pneumoniae
Ureaplasma urealyticum

Pregnancy and breastfeeding
No harm has been found with use during pregnancy. However, there are no adequate well-controlled studies in pregnant women.The safety of the medication during breastfeeding is unclear. It was reported that because only low levels are found in breast milk and the medication has also been used in young children, it is unlikely that breastfed infants would have adverse effects. Nevertheless, it is recommended that the drug be used with caution during breastfeeding. Airway diseases
Azithromycin appears to be effective in the treatment of chronic obstructive pulmonary disease through its suppression of inflammatory processes. And potentially useful in asthma and sinusitis via this mechanism. Azithromycin is believed to produce its effects through suppressing certain immune responses that may contribute to inflammation of the airways. Adverse effects
Most common adverse effects are diarrhea (5%), nausea (3%), abdominal pain (3%), and vomiting. Fewer than 1% of people stop taking the drug due to side effects. Nervousness, skin reactions, and anaphylaxis have been reported. Clostridium difficile infection has been reported with use of azithromycin. Azithromycin does not affect the efficacy of birth control unlike some other antibiotics such as rifampin. Hearing loss has been reported.Occasionally, people have developed cholestatic hepatitis or delirium.